Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 23, Issue 7, 2013, Pages 2007-2013

  Elagawany, Mohamed ^a,b,c   Ibrahim, Mohamed A ^a,b,d   Ali Ahmed, Hany Emary ^c,e   El Etrawy, A Sh ^b   Ghiaty, Adel ^c   Abdel Samii, Zakaria K ^d   El Feky, Said A ^d   Bajorath, Jürgen ^f  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Misr University for Science and Technology   (Egypt)

^c Al Azhar University   (Egypt)

^d Zagazig University   (Egypt)

^e TAIBAH UNIVERSITY   (Saudi Arabia)

^f UNIVERSITY OF BONN   (Germany)

Author keywords

Docking; GSK3; Kinases; Phthalazinone; Pyridazinone

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; HYMENIALDISINE; PHTHALAZINONE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCULATION; CANCER CELL CULTURE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; MOLECULAR DOCKING; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CASEIN KINASE I; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE 5; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; GLYCOGEN SYNTHASE KINASE 3; HCT116 CELLS; HL-60 CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIDAZINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84875229563     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2013.02.027     Document Type: Article

References (29)

1. J. Zhang, P.L. Yang, and N.S. Gray Nat. Rev. Cancer 9 2009 28
2. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam Science 298 2002 1912
3. T. Hunter Cell 80 1995 225
4. H. Galons, N. Oumata, and L. Meijer Expert Opin. Ther. Patents 20 2010 377
5. M. Knockaert, P. Greengard, and L. Meijer Trends Pharmacol. Sci. 23 2002 417
6. A. Huwe, R. Mazitschek, and A. Giannis Angew. Chem., Int. Ed. 42 2003 2122
7. P. Polychronopoulos, P. Magiatis, A.-L. Skaltsounis, V. Myrianthopoulos, E. Mikros, A. Tarricone, A. Musacchio, S.M. Roe, L. Pearl, M. Leost, P. Greengard, and L. Meijer J. Med. Chem. 47 2004 935
8. N. Oumata, K. Bettayeb, Y. Ferandin, L. Demange, A. Lopez-Giral, M.-L. Goddard, V. Myrianthopoulos, E. Mikros, M. Flajolet, P. Greengard, L. Meijer, and H. Galons J. Med. Chem. 51 2008 5229
9. L. Meijer, M. Flajolet, and P. Greengard Trends Pharm. Sci. 25 2004 471
10. L. Meijer, A.M.W.H. Thunnissen, A.W. White, M. Garnier, M. Nikolic, L.H. Tsai, J. Walter, K.E. Cleverley, P.C. Salinas, Y.Z. Wu, J. Biernat, E.M. Mandelkow, S.H. Kim, and G.R. Pettit Chem. Biol. 7 2000 51
11. U. Knippschild, A. Gocht, S. Wolff, N. Hubet, J. Löhler, and M. Stöter Cell. Signal. 17 2005 675
12. N. Oumata, K. Bettayeb, Y. Ferandin, L. Demange, A. Lopez-Giral, M.-L. Goddard, V. Myrianthopoulos, E. Mikros, M. Flajolet, P. Greengard, L. Meijer, and H. Galons J. Med. Chem. 51 2008 5229
13. G.V. Shah, A. Muralidharan, S. Thomas, M. Gokulgandhi, M. Mudit, M. Khanfar, and K.A. El Sayed Mol. Cancer Ther. 8 2009 509
14. K. Iqbal, and I. Grundke-Iqbal J. Cell. Mol. Med. 12 2008 38
15. A. Martinez, M. Alonso, A. Castro, C. Perez, and F.J. Moreno J. Med. Chem. 45 2002 1292
16. A. Martinez, M. Alonso, A. Castro, I. Dorronsoro, J.L. Gelpi, F.J. Luque, C. Perez, and F.J. Moreno J. Med. Chem. 48 2005 7103
17. A. Castro, A. Encinas, C. Gil, S. Brase, W. Porcal, C. Perez, F.J. Moreno, and A. Martinez Bioorg. Med. Chem. 16 2008 495
18. M.O. Taha, Y. Bustanji, M.A.S. Al-Ghussein, M. Mohammad, H. Zalloum, I.M. Al-Masri, and N. Atallah J. Med. Chem. 51 2008 2062
19. M.T. Hamann, D. Alonso, E. Martín-Aparicio, A. Fuertes, J. Pérez-Puerto, A. Castro, S. Morales, M.L. Navarro, M. del Monte-Millán, M. Medina, H. Pennaka, A. Balaiah, J. Peng, J. Cook, S. Wahyuono, and A. Martínez J. Nat. Prod. 70 2007 1397
20. G. McMahon, L. Sun, C. Liang, and C. Tang Curr. Opin. Drug Disc. Dev. 1 1998 131
21. J.L. Adams, and D. Lee Curr. Opin. Drug Disc. Dev. 2 1999 96
22. C. Garcia-Echeverria, P. Traxler, and D.B. Evans Med. Res. Rev. 20 2000 28
23. Watterson, D. M.; Van Eldik, L.; Haiech, J.; Hibert, M.; Bourguignon, J.-J.; Velentza, A.; Hu, W.; Zasadzki, M. WO 2006050389, 2006.
24. B.M. Fox, K. Iio, K. Li, R. Choi, T. Inaba, S. Jackson, S. Sagawa, B. Shan, M. Tanaka, A. Yoshida, and F. Kayser Bioorg. Med. Chem. Lett. 20 2010 6030
25. X.-Y. Sun, C. Hu, X.-Q. Deng, C.-X. Wei, Z.-G. Sun, and Z.-S. Quan Eur. J. Med. Chem. 45 2010 4807
26. P. Raboisson, B. Mekonnen, and N.P. Peet Tetrahedron Lett. 44 2003 2919
27. K. Abouzid, M. Abdel Hakeem, O. Khalil, and Y. Maklad Bioorg. Med. Chem. 16 2008 382
28. MOE (The Molecular Operating Environment) Version 2008.06, Chemical Computing Group Inc. http://www.chemcomp.com.
29. T. Liu, Y. Lin, X. Wen, R.N. Jorissen, and M.K. Gilson Nucleic Acids Res. 35 2007 198